FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070161934> ?p ?o ?g. }

• W2070161934 endingPage "227" @default.
• W2070161934 startingPage "227" @default.
• W2070161934 abstract "Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective Naoky Tsai,1 Lennox Jeffers,2 Lael Cragin,3 Sonja Sorensen,3 Wenqing Su,3 Lisa Rosenblatt,4 Hong Tang,4 Tony Hebden,4 Timothy Juday41John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; 2University of Miami School of Medicine, Miami, FL, USA; 3United BioSource Corporation, Bethesda, MD, USA; 4Bristol-Myers Squibb Company, Plainsboro, NJ, USABackground: Decompensated cirrhosis is a serious clinical complication of chronic hepatitis B (CHB) that places a large economic burden on the US health care system. Although entecavir has been shown to improve health outcomes in a cost-effective manner in mixed populations of CHB patients, the cost-effectiveness of entecavir has not been evaluated in CHB patients with decompensated cirrhosis.Methods: This study assessed the cost-effectiveness of entecavir versus adefovir, from a US payer perspective, in CHB patients with decompensated cirrhosis, using a health-state transition Markov model with four health states: hepatocellular carcinoma (HCC), HCC-free survival, post-liver transplant, and death. The model considered a hypothetical patient population similar to that included in a randomized controlled trial in the target population (ETV-048): predominantly male (74%), Asian (54%), mean age 52 years, hepatic decompensation (Child–Pugh score ≥ seven), hepatitis B e antigen-positive or -negative, treatment-naïve or lamivudine-experienced, and no liver transplant history. Clinical inputs were based on cumulative safety results for ETV-048 and published literature. Costs were obtained from published literature. Costs and outcomes were discounted at 3% per annum.Results: For 1000 patients over a 3-year time horizon, predicted overall survival and HCC-free survival were longer with entecavir than with adefovir (2.35 versus 2.30 years and 2.11 versus 2.03 years, respectively). Predicted total health care costs were $889 lower with entecavir than with adefovir ($91,878 versus $92,768). For incremental cost/life-year gained and incremental cost/HCC-free-year gained, entecavir was less costly and more effective than adefovir. Sensitivity analyses found the results to be robust to plausible variations in health-state costs and discount rate.Conclusion: This analysis suggests that entecavir improves survival outcomes in a cost-saving manner compared with adefovir in CHB patients with hepatic decompensation.Keywords: hepatocellular carcinoma, antiviral, survival, health economics, incremental net benefit" @default.
• W2070161934 created "2016-06-24" @default.
• W2070161934 creator A5002539396 @default.
• W2070161934 creator A5014268039 @default.
• W2070161934 creator A5019263613 @default.
• W2070161934 creator A5042995852 @default.
• W2070161934 creator A5052690217 @default.
• W2070161934 creator A5054497237 @default.
• W2070161934 creator A5054707936 @default.
• W2070161934 creator A5066909163 @default.
• W2070161934 creator A5071098192 @default.
• W2070161934 date "2012-08-01" @default.
• W2070161934 modified "2023-09-30" @default.
• W2070161934 title "Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective" @default.
• W2070161934 cites W1990880232 @default.
• W2070161934 cites W1995612767 @default.
• W2070161934 cites W1998686118 @default.
• W2070161934 cites W2004054613 @default.
• W2070161934 cites W2004296799 @default.
• W2070161934 cites W2011794322 @default.
• W2070161934 cites W2022625249 @default.
• W2070161934 cites W2031095503 @default.
• W2070161934 cites W2031317669 @default.
• W2070161934 cites W2055409989 @default.
• W2070161934 cites W2068100797 @default.
• W2070161934 cites W2075528292 @default.
• W2070161934 cites W2092813178 @default.
• W2070161934 cites W2098472552 @default.
• W2070161934 cites W2106415541 @default.
• W2070161934 cites W2123733952 @default.
• W2070161934 cites W2123873622 @default.
• W2070161934 cites W2129802081 @default.
• W2070161934 cites W2138424758 @default.
• W2070161934 cites W2181686257 @default.
• W2070161934 cites W2187843068 @default.
• W2070161934 cites W2315027248 @default.
• W2070161934 cites W1493990568 @default.
• W2070161934 cites W2463585544 @default.
• W2070161934 doi "https://doi.org/10.2147/ceor.s31784" @default.
• W2070161934 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3430439" @default.
• W2070161934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22977309" @default.
• W2070161934 hasPublicationYear "2012" @default.
• W2070161934 type Work @default.
• W2070161934 sameAs 2070161934 @default.
• W2070161934 citedByCount "2" @default.
• W2070161934 countsByYear W20701619342014 @default.
• W2070161934 countsByYear W20701619342016 @default.
• W2070161934 crossrefType "journal-article" @default.
• W2070161934 hasAuthorship W2070161934A5002539396 @default.
• W2070161934 hasAuthorship W2070161934A5014268039 @default.
• W2070161934 hasAuthorship W2070161934A5019263613 @default.
• W2070161934 hasAuthorship W2070161934A5042995852 @default.
• W2070161934 hasAuthorship W2070161934A5052690217 @default.
• W2070161934 hasAuthorship W2070161934A5054497237 @default.
• W2070161934 hasAuthorship W2070161934A5054707936 @default.
• W2070161934 hasAuthorship W2070161934A5066909163 @default.
• W2070161934 hasAuthorship W2070161934A5071098192 @default.
• W2070161934 hasBestOaLocation W20701619341 @default.
• W2070161934 hasConcept C126322002 @default.
• W2070161934 hasConcept C187212893 @default.
• W2070161934 hasConcept C203014093 @default.
• W2070161934 hasConcept C2522874641 @default.
• W2070161934 hasConcept C2776175608 @default.
• W2070161934 hasConcept C2777214474 @default.
• W2070161934 hasConcept C2777382497 @default.
• W2070161934 hasConcept C2777869810 @default.
• W2070161934 hasConcept C2778019345 @default.
• W2070161934 hasConcept C2778721985 @default.
• W2070161934 hasConcept C2779517838 @default.
• W2070161934 hasConcept C2780593183 @default.
• W2070161934 hasConcept C2908647359 @default.
• W2070161934 hasConcept C71924100 @default.
• W2070161934 hasConcept C90924648 @default.
• W2070161934 hasConcept C99454951 @default.
• W2070161934 hasConceptScore W2070161934C126322002 @default.
• W2070161934 hasConceptScore W2070161934C187212893 @default.
• W2070161934 hasConceptScore W2070161934C203014093 @default.
• W2070161934 hasConceptScore W2070161934C2522874641 @default.
• W2070161934 hasConceptScore W2070161934C2776175608 @default.
• W2070161934 hasConceptScore W2070161934C2777214474 @default.
• W2070161934 hasConceptScore W2070161934C2777382497 @default.
• W2070161934 hasConceptScore W2070161934C2777869810 @default.
• W2070161934 hasConceptScore W2070161934C2778019345 @default.
• W2070161934 hasConceptScore W2070161934C2778721985 @default.
• W2070161934 hasConceptScore W2070161934C2779517838 @default.
• W2070161934 hasConceptScore W2070161934C2780593183 @default.
• W2070161934 hasConceptScore W2070161934C2908647359 @default.
• W2070161934 hasConceptScore W2070161934C71924100 @default.
• W2070161934 hasConceptScore W2070161934C90924648 @default.
• W2070161934 hasConceptScore W2070161934C99454951 @default.
• W2070161934 hasLocation W20701619341 @default.
• W2070161934 hasLocation W20701619342 @default.
• W2070161934 hasLocation W20701619343 @default.
• W2070161934 hasLocation W20701619344 @default.
• W2070161934 hasOpenAccess W2070161934 @default.
• W2070161934 hasPrimaryLocation W20701619341 @default.
• W2070161934 hasRelatedWork W1964151379 @default.
• W2070161934 hasRelatedWork W2021066789 @default.

• next